11.05.20: Not intended for U.S. and UK Media

Bayer to Present Data from Growing Oncology Portfolio at the ASCO20 Virtual Scientific ProgramData on final analysis of overall survival (OS) from the Phase III ARAMIS trial investigating darolutamide (Nubeqa™) in men with non-metastatic castration-resistant prostate cancer (nmCRPC) / Updated efficacy and safety data for larotrectinib (Vitrakvi®) from an expanded set of adult patients with TRK fusion cancer and a quality of life (QoL) analysis in adult and pediatric patients / New safety and efficacy data from established compounds including radium-223 dichloride (Xofigo®) and regorafenib (Stivarga®)mehr ...
Source: Bayer IR Newsfeed: Events - Category: Pharmaceuticals Source Type: news